A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Homburg An D. Saar, 66421, Germany
Fukuyama-shi, Hiroshima 7200001, Japan
Amagasaki-shi, Hyōgo 6608550, Japan
Nishinomiya-shi, Hyōgo 6638501, Japan
Kitaadachi-gun, Saitama 3620806, Japan
Chuo-ku, Tokyo 1040045, Japan
Ube-shi, Yamaguchi 7550241, Japan
Df, Mexico City 06720, Mexico
Romania, 400015, Romania